Listen Now
Topics Covered
- The Treatment of Triple Negative Breast Cancer, in the Context of COVID-19
- Why Clinical Trials Are Important as a Treatment Option for Triple Negative Breast Cancer
- What Happens in a Clinical Trial
- New Research in the Treatment of Triple Negative Breast Cancer (TNBC)
- Investigational New Drugs in Clinical Trials
- The Meaning of Informed Consent
- Benefits & Risks of Participation
- How & Where Clinical Trials are Conducted
- How to Participate in Clinical Trials
- Specific Questions to Ask Your Health Care Team about Clinical Trials
- Accessing Resources for Clinical Trials
- Questions for Our Panel of Experts
Our Panel of Experts

Generosa Grana, MD, FACP
Medical Director, MD Anderson Cancer Center at Cooper, Division Head, Hematology & Medical Oncology, The Cooper Health System, Professor of Medicine, Cooper Medical School at Rowan University

Minetta C. Liu, MD
Professor and Research Chair, Division of Medical Oncology, Department of Oncology, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Medical Director, Office of Specialty Collaborations and Contracts, Co-Leader, Genomics in Action Strategic Priority, Center for Individualized Medicine, Mayo Clinic

Elizabeth Jane Cathcart-Rake, MD
Staff Physician, Hematology/Oncology, Saint Luke’s Cancer Specialist in Breast Cancer, Saint Luke’s Cancer Institute

Hayley Dinerman, JD
Co-Founder and Executive Director, Triple Negative Breast Cancer Foundation®

Ricki Fairley
Vice President, Strategic Partnerships and National Programs, Sisters Network® Inc. – A National African American Breast Cancer Survivorship Network

Lauren Chatalian, MSW
Women and Children's Program Coordinator, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on June 17, 2020.